Navigation Links
CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS

nts and patent applications that were filed from 1998 to 2006 in the areas of RNAi target sequences, RNAi chemistry and RNAi delivery. The Company was founded by CytRx and RNAi pioneers Craig Mello, Ph.D., 2006 Nobel Laureate for discovering RNAi and inventing RNAi therapeutics; Tariq M. Rana, Ph.D., inventor of fundamental technology for stabilizing RNAi and of RNAi nanotransporters; Greg Hannon, Ph.D., discoverer of RNAi mechanism (RISC) and short hairpin RNAi (shRNAi); and Michael Czech, Ph.D., a leader in the application of RNAi to diabetes and obesity. RXi's CEO, Tod Woolf, Ph.D., previously co-invented and commercialized STEALTH(TM) RNAi, one of the most widely used second-generation RNAi research products.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties regarding regulatory approvals for future clinical testing of arimoclomol, including CytRx's planned Phase IIb clinical trial, and the scope of the clinical testing that may be required by regulatory authorities for arimoclomol, uncertainties regarding the timing and amount of revenues, if any, that will be realized by CytRx from the commercialization of arimoclomol, the significant time and expense that will be incurred in developing any of the potential commercial applications for arimoclomol and the potential need for additional capital to fund the development of arimoclomol, as well as other risks or uncertainties described in CytRx's most recently filed SEC documents, such as its most recent annual report on Form 10-K and any current reports on Form 8-K filed since the date of the last Form 10-K. All forward-looking statements are based upon information avail
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:8/18/2008)... BETHESDA, Md., Aug. 18 /...ical company developing novel, proprietary,antibod...autoimmune,diseases, will host a webcast and confe...at 10:00 a.m. Eastern Time (4:00 p.m. Central Euro...ere published in the Journal,SCIENCE on August 15,...
(Date:8/14/2008)... PRINCETON, N.J., Aug. 14 /PRNewswire-FirstCall/...stage pharmaceutical company committed to,discover... treat viral,infections, reported unaudited financ...e 30, 2008. Pharmasset reported a net loss attribu...a loss per share of $0.69 for the,quarter ended Ju...
(Date:8/13/2008)... Provides risk managers with comprehensive overvi...posure and required coverage, CHICAGO, Aug. 13 /P...,technology arm of Aon Corporation (NYSE: AOC ) a...ce solutions, today announced it has launched a ne...he market-leading,browser-based risk management i...
(Date:8/13/2008)... Reduction of CRP with ISIS 353512 could provide ...renal and inflammatory diseases, CARLSBAD, Calif....ticals, Inc. (Nasdaq: ISIS ) announced today it h...tisense drug that inhibits the,production of C-rea...vated,in patients with a variety of diseases inclu...
Breaking Medicine Technology:Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 2Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 3Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 4Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 2Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 3Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 4Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 5Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 6Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 7Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 8Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 9Aon eSolutions Launches Clinical Trials Module 2Aon eSolutions Launches Clinical Trials Module 3Aon eSolutions Launches Clinical Trials Module 4Isis Initiates Clinical Trial of CRP Drug 2Isis Initiates Clinical Trial of CRP Drug 3WuXi PharmaTech 28NYSE 3A WX 29 Promotes Edward Hu to COO 2442 1WuXi PharmaTech 28NYSE 3A WX 29 Promotes Edward Hu to COO 2442 2Pharmos Corporation Announces Board and Management Changes 2440 1Pharmos Corporation Announces Board and Management Changes 2440 2Pharmos Corporation Announces Board and Management Changes 2440 3Biodel Inc Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject 28TM 29 and Plans Manufacturing Facility for VIAject 28TM 29 1136 1Biodel Inc Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject 28TM 29 and Plans Manufacturing Facility for VIAject 28TM 29 1136 2Biodel Inc Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject 28TM 29 and Plans Manufacturing Facility for VIAject 28TM 29 1136 3Takeda Submits New Drug Application for Alogliptin 28SYR 322 29 in the U S 1134 1Takeda Submits New Drug Application for Alogliptin 28SYR 322 29 in the U S 1134 2Takeda Submits New Drug Application for Alogliptin 28SYR 322 29 in the U S 1134 3Takeda Submits New Drug Application for Alogliptin 28SYR 322 29 in the U S 1134 4
...ss.--(BUSINESS WIRE)--Mar 14, 2007 - ArQule, Inc.,...ociety of,Clinical Oncology (ASCO) has accepted fo... 197 (A Phase 1 Dose Escalation Study of,ARQ 197, ...ients,with Metastatic Solid Tumors) at the 43rd AS...s presentation will describe findings,from a Phase...
...lough Announces Presentation Of Phase II Trial Res...t The 2007 Annual,Meeting Of The American College ...6, 2007 /PRNewswire-FirstCall/ --,Schering-Plough ...ase II trial of its novel oral thrombin receptor a...e 2007 annual Scientific Sessions,of the of Cardio...
Other Medicine Technology:ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO 2ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO 3ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO 4Media Advisory: ACC Updated Schedule 2
(Date:8/20/2008)...usetts General Hospital (MGH) investigators have f...em cell appeared to protect gastrointestinal tissu...ir report published in the journal Stem Cells , t...icine report that mesenchymal stem cells (MSCs), k...allowed the regeneration of the gastrointestinal l...
(Date:8/20/2008)...NGTON, Aug. 20 /PRNewswire-USNewswire/ -- Yesterda... admitted to Huron Hospital after,suffering an ane...Ohio. At,the present time Rep. Tubbs Jones, condit...are available., Tuesday,s condition followed a fu...ming forum on electoral reform, scheduled for Sept...
(Date:8/20/2008)... Micro(R) PUMP and ELLEgirl.com Send Four Girls to...Summer, LOS ANGELES, Aug. 20 /PRNewswire/ -- Reti...eenage Web site ELLEgirl.com to send four contest,...Camp in Santa Monica,California. With the new sch...mpower girls to become successful women by helping...
(Date:8/20/2008)...IEGO, Aug. 20 /PRNewswire/ --You,re late for work,...r car won,t start. How do you deal with,the rising...ash out in,frustration, how you deal with anger af...r children and even your career., As hard as we m...push,our buttons. While feeling anger isn,t a bad ...
Breaking Medicine News(10 mins):Health News:Bone marrow stem cells may help control inflammatory bowel disease 2Health News:Bone marrow stem cells may help control inflammatory bowel disease 3Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 2Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 3Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 4Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 5Health News:Taming Your Temper: Learning to Turn Down the Heat 2
...oLipo(TM) laser module received clearance from the...ted lipolysis, and its BBL(TM) broadband pulsed li...les. ProLipo represents the latest technological ...ber-delivered laser energy to target fatty tissue....
... food for its 2.3 million soldiers, with the milit... recent spate of health scandals, state media rep...e or substandard food products and eliminating the... eating from the same plate, according to an annou...
...r a day, the Australian police finally announced t... in southern India, was being charged with provid...em a mobile phone SIM card. His cousin Sabeel Ahm... in Runcorn, southeast of Liverpool, has been accu...
... registry of pregnancies and abortions to stem sel... according to a report. India has only 927 femal...ldwide average of 1,050 females -- mainly due to s...e country where many people prefer to have male ch...
Other Medicine News:Health News:Sciton Receives FDA Clearance for Lipolysis and Wrinkle Treatment 2Health News:Three Doctors Charged So Far in the UK Bombing Case 2Health News:Three Doctors Charged So Far in the UK Bombing Case 3Health News:Three Doctors Charged So Far in the UK Bombing Case 4Health News:India to Monitor Pregnancies to Check Girl Foeticide: Report 2
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
Medicine Products: